Health ❯ Biotechnology

Drug Development

Clinical Trials Gene Therapy Therapeutics Research Investments Molecular Transport Protein Applications Vaccine Design Regulatory Affairs Antibodies Weight Loss Drugs Cancer Treatment Alzheimer's Drugs Press Releases Biosimilars Company Closures Protein Therapeutics AI in Healthcare Clinical Efficacy Neurodegenerative Disorders Cancer Research Viral Hepatitis Cardiovascular Drugs Obesity Treatments Clinical Testing Monoclonal Antibodies Biologics Research Capabilities Allosteric Modulators Clinical Research Immunotherapies Immunotherapy Vaccine Research Cell Therapy

FDA Approves Isembyld, First Muscle‑Directed Therapy for Spinal Muscular Atrophy

Isembyld is an IV add‑on to existing SMN2 treatments that showed motor improvement in children and will begin U.S. shipments.

FDA Panel Rejects Deramiocel Cardiac Claim After Lancet Publishes HOPE‑3 Results

ImmunityBio Investors Face May 26 Lead-Plaintiff Deadline in Securities Suit Tied to FDA Anktiva Rebuke

ImmunityBio Investors Urged to Seek Lead Role in Suit After FDA Rebuke Over Anktiva Ads

Senhwa Signs MOU With GEM for Up to NT$500 Million to Speed AI-Driven Cancer R&D

Nuclera Extends Series C to $87 Million to Accelerate Full-Format Antibody Workflows

Sanofi Secures Global Rights to ADEL’s Alzheimer’s Antibody in Deal Worth Up to $1.04 Billion

Prolynx Raises $70 Million to Advance Ultra-Long-Acting Obesity Drugs

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug

Lilly and Breakthrough to Open Gateway Labs Biotech Incubator at 2300 Market in Philadelphia

FDA Flags Possible License Revocation for Sarepta’s Elevidys